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Introduction {#jgh14154-sec-0005}
============

Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in Australia.[1](#jgh14154-bib-0001){ref-type="ref"} While diagnoses are predominantly made in those at older ages, certain groups are at increased risk of early‐onset CRC, largely as a result of inherited genetic mutations.[2](#jgh14154-bib-0002){ref-type="ref"} Lynch syndrome (LS), an autosomal dominant condition, is a well‐known genetic syndrome that increases risk of early‐onset CRC (average age at diagnosis is 42 years for men and 47 years for women[3](#jgh14154-bib-0003){ref-type="ref"}). Caused by a germline mutation in one of the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2), LS is characterized by tumors that develop with high levels of microsatellite instability (MSI) and loss of expression of one or more of the MMR proteins, collectively referred to as tumor MMR deficiency.

Lynch syndrome is estimated to cause 1--3% of all CRC cases[4](#jgh14154-bib-0004){ref-type="ref"} with carriers experiencing accelerated carcinogenesis and an increased lifetime risk for CRC (10--47% by age 70 years[5](#jgh14154-bib-0005){ref-type="ref"}, [6](#jgh14154-bib-0006){ref-type="ref"}, [7](#jgh14154-bib-0007){ref-type="ref"} compared with 4--5%[8](#jgh14154-bib-0008){ref-type="ref"} in the general population) as well as predisposing individuals to other cancers.[9](#jgh14154-bib-0009){ref-type="ref"}, [10](#jgh14154-bib-0010){ref-type="ref"} A diagnosis of LS aids clinical decision‐making, including more extensive surgery and highly intensive long‐term surveillance, which impacts patient outcomes.[4](#jgh14154-bib-0004){ref-type="ref"} Furthermore, a diagnosis permits cascade testing of at‐risk family members to determine LS carrier status, thus enabling the commencement of intensive surveillance, which has been shown to lead to a reduction in LS‐related cancer incidence and mortality.[11](#jgh14154-bib-0011){ref-type="ref"}, [12](#jgh14154-bib-0012){ref-type="ref"}, [13](#jgh14154-bib-0013){ref-type="ref"}, [14](#jgh14154-bib-0014){ref-type="ref"}, [15](#jgh14154-bib-0015){ref-type="ref"}

Historically, LS testing has been guided using the Amsterdam or revised Bethesda criteria, both of which rely on obtaining an accurate family history[12](#jgh14154-bib-0012){ref-type="ref"} but have limited sensitivity and specificity for LS detection and are poorly implemented in routine clinical practice.[4](#jgh14154-bib-0004){ref-type="ref"}, [16](#jgh14154-bib-0016){ref-type="ref"}, [17](#jgh14154-bib-0017){ref-type="ref"} More recently, screening for LS has begun with tumor testing for MMR deficiency, prior to proceeding to germline MMR gene testing.[17](#jgh14154-bib-0017){ref-type="ref"}, [18](#jgh14154-bib-0018){ref-type="ref"}, [19](#jgh14154-bib-0019){ref-type="ref"} However, as MMR deficiency can also be caused by sporadic somatic hypermethylation of the *MLH1* gene promoter, tumors showing loss of MLH1/PMS2 protein expression require further testing (with either somatic *MLH1* methylation testing or *BRAF* V600E somatic mutation testing). If LS is still suspected after these tumor tests, genetic testing is offered in association with genetic counseling.

Within Australia, there is no national policy for LS screening; however, the National Health and Medical Research Council recently recommended universal screening,[20](#jgh14154-bib-0020){ref-type="ref"} as a means of increasing identification of carriers and their at‐risk relatives. While this recommendation is in line with other juristrictions,[4](#jgh14154-bib-0004){ref-type="ref"}, [21](#jgh14154-bib-0021){ref-type="ref"} no cost‐effectiveness analyses have been conducted in the Australian setting and therefore the optimal screening strategy remains unclear.

We aimed to determine the cost‐effectiveness of CRC tumor screening to identify LS at different age‐at‐diagnosis thresholds for two alternative tumor screening pathways using data from the Australian setting.

Methods {#jgh14154-sec-0006}
=======

Overview {#jgh14154-sec-0007}
--------

We developed a decision analysis model to simulate LS screening in individuals with CRC to estimate the annual yield and costs associated with identifying LS this population. For tumors exhibiting loss of *MLH1*/PMS2 expression by MMR immunohistochemistry (IHC), we tested two alternative pathways based on the follow‐up tumor test (*MLH1* methylation test or a *BRAF* V600E mutation test). The primary focus was to determine how yield and cost would vary for each pathway by age‐at‐diagnosis and compare the incremental differences within and between the pathways.

Data {#jgh14154-sec-0008}
----

Model parameters were based on two Australian research studies, the Australasian Colorectal Cancer Family Registry and the Melbourne Collaborative Cohort Study, which have been systematically characterized for LS. Detailed information about the recruitment strategy and tumor testing for these studies has been previously reported.[18](#jgh14154-bib-0018){ref-type="ref"} In brief, the Australasian Colorectal Cancer Family Registry recruited population‐based incident CRC cases of individuals aged 18--59 years (eligible cases *n* = 813) between 1997 and 2007. The Melbourne Collaborative Cohort Study is an Australian cohort study of 41 513 Melbourne residents recruited during 1990--1994 with age range at recruitment of 27--80 years. Data from 826 CRC cases diagnosed from recruitment until 2010 and aged 41--86 years at diagnosis were used for this analysis.

Colorectal cancer tumor samples from both studies were tested for MMR protein expression using IHC. Tumors showing MMR deficiency underwent germline testing to identify a MMR gene mutation and confirm LS diagnosis. For tumors demonstrating loss of *MLH1*/PMS2 expression by IHC, testing for tumor *MLH1* promoter hypermethylation and *BRAF* V600E somatic mutation were performed, and only those cases with no evidence of somatic *MLH1* methylation or *BRAF* wild‐type underwent germline testing of *MLH1* gene.

Decision analysis model {#jgh14154-sec-0009}
-----------------------

Using TreeAge Pro 2016 (Williamstown, Massachusetts), we developed a decision analysis model to simulate LS screening. For tumors exhibiting loss of *MLH1*/PMS2 expression by MMR IHC, we assessed two screening pathways for identifying LS based on follow‐up tumor testing. In the first model (*MLH1*‐Pathway), IHC was followed by somatic *MLH1* methylation testing (Fig. [1](#jgh14154-fig-0001){ref-type="fig"}), while in the second model (*BRAF*‐Pathway), IHC was followed by *BRAF* V600E mutation testing (Fig. [2](#jgh14154-fig-0002){ref-type="fig"}). For each pathway, we simulated 1000 CRC cases and assumed 100% participation in tumor and genetic testing at all stages. Once a diagnosis of CRC has been made, eligible individuals entered the LS screening pathway and progressed based on age‐specific probabilities (Figs [1](#jgh14154-fig-0001){ref-type="fig"}, [2](#jgh14154-fig-0002){ref-type="fig"}). Costs are applied at appropriate time points along the pathway, such as when a test is conducted or when genetic counseling would be initiated.

![*MLH1*‐Pathway with age‐specific probabilities of progressing through the Lynch syndrome (LS) screening pathway. ^†^Probability of meeting inclusion criteria in the age‐restricted scenarios is based on the age distribution of colorectal cancer (CRC) incidence data from 2008 to 2012.[8](#jgh14154-bib-0008){ref-type="ref"} ^‡^MMR deficiency is determined by testing with IHC and is defined as loss of MMR expression in one or more of the four MMR genes (MLH1, PMS2, MSH2, and MSH6). ^§^Progression through the pathway is based on probabilities derived from Buchanan *et al*.[18](#jgh14154-bib-0018){ref-type="ref"} These probabilities differ slightly as we considered LS cases that did not show MMR deficiency with IHC to be missed cases (three cases in screening \< 60 and screening \< 70 and four cases in universal). In addition, one LS case was excluded from the probabilities in our analysis because although the case showed PMS2 loss, genetic testing identified an MLH1 mutation, and this could not be factored into the model. Using screening \< 50 as the example, 7.6% of all CRC cases were eligible for testing with IHC to determine MMR deficiency status and 13.5% were MMR deficient. Of these, 52.8% had loss of MLH1/PMS2, 18.1% had loss of MSH2/MSH6, 12.5% had loss of MSH6 only, and 16.7% had loss of PMS2 only. Of the tumors with of MHL1/PMS2, 92.1% were unmethylated and went on for germline testing. LS was confirmed in 66.7% of CRC cases demonstrating MLH1/PMS2 loss (excluding *MLH1*‐methylated CRCs), 61.5% of the cases demonstrating MSH2/MSH6 loss, 77.8% of the cases demonstrating MSH6 loss, and 66.7% of the cases demonstrating PMS2 only. CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; \< 60, age‐specific probabilities for CRC cases aged under 60 years; 60--69, age‐specific probabilities for CRC cases aged between 60 and 69 years; 70+, age‐specific probabilities for CRC cases aged over 70 years.](JGH-33-1737-g001){#jgh14154-fig-0001}

![*BRAF*‐Pathway with age‐specific probabilities of progressing through the Lynch syndrome (LS) screening pathway. ^†^Probability of meeting inclusion criteria in the age‐restricted scenarios is based on the age distribution of colorectal cancer (CRC) incidence data from 2008 to 2012.[8](#jgh14154-bib-0008){ref-type="ref"} ^‡^MMR deficiency is determined by testing with IHC and is defined as loss of MMR expression in one or more of the four MMR genes (MLH1, PMS2, MSH2, and MSH6). ^§^Progression through the pathway is based on probabilities derived from Buchanan *et al*.[18](#jgh14154-bib-0018){ref-type="ref"} These probabilities differ slightly as we considered LS cases that did not show MMR deficiency with IHC to be missed cases (three cases in screening \< 60 and screening \< 70 and four cases in universal). In addition, one LS case was excluded from the probabilities in our analysis because although the case showed PMS2 loss, genetic testing identified an MLH1 mutation, and this could not be factored into the model. Using screening \< 50 as the example, 7.6% of all CRC cases were eligible for testing with IHC to determine MMR deficiency status and 13.5% were MMR deficient. Of these, 52.8% had loss of MLH1/PMS2, 18.1% had loss of MSH2/MSH6, 12.5% had loss of MSH6 only, and 16.7% had loss of PMS2 only. Of the tumors with of MHL1/PMS2, 97.4% were *BRAF* wild type and went on for germline testing. LS was confirmed in 37.8% of CRC cases demonstrating MLH1/PMS2 loss, 61.5% of the cases demonstrating MSH2/MSH6 loss, 77.8% of the cases demonstrating MSH6 loss, and 66.7% of the cases demonstrating PMS2 only. CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; \< 60, age‐specific probabilities for CRC cases aged under 60 years; 60--69, age‐specific probabilities for CRC cases aged between 60 and 69 years; 70+, age‐specific probabilities for CRC cases aged over 70 years.](JGH-33-1737-g002){#jgh14154-fig-0002}

Screening scenarios {#jgh14154-sec-0010}
-------------------

For this analysis, we used empirical data[18](#jgh14154-bib-0018){ref-type="ref"} to assess four age‐at‐diagnosis scenarios: screening \< 50, screening \< 60, screening \< 70, and universal screening. In the reference scenario, screening \< 50, screening was restricted to CRC diagnoses occurring before the age of 50 years. Screening \< 60 expanded tumor screening to include those aged 50--59 years, and screening \< 70 is a further expansion to include cases aged 60--69 years. The universal scenario included screening of all incident CRC diagnoses regardless of age. The probability of meeting the LS screening eligibility criteria for the age‐restricted scenarios was based on Australian CRC incidence data from 2008 to 2012.[8](#jgh14154-bib-0008){ref-type="ref"}

Cost assumptions {#jgh14154-sec-0011}
----------------

The cost of MMR IHC was provided by The Royal College of Pathologists of Australasia Benchmarking in Pathology Quality Assurance Program (St. Leonards, NSW) (2013) results (Dr Tony Badrick, pers. comm.). For the *MLH1* methylation testing, cost data were provided by PathWest Laboratory Medicine, Nedlands, the sole government pathology service for Western Australia (Dr Benhur Amanuel, pers. comm.). The cost of *BRAF* V600E testing was taken from MBS Online[22](#jgh14154-bib-0022){ref-type="ref"} (Table [1](#jgh14154-tbl-0001){ref-type="table"}). Germline testing costs were provided by the Department of Diagnostic Genomics, PathWest Laboratory Medicine, Nedlands, the primary laboratory for genetic testing in Western Australia (Dr Karen Carpenter, pers. comm.). The costs for genetic counseling were obtained from primary sources at Genetic Services of Western Australia (Subiaco, WA), including the Business Unit and genetic counselors (Anne Hawkins and Cassandra Nichols, pers. comm.).

###### 

Cost parameters

  Parameter                                                                                      Cost                                          Source                                                                                               Range (\$A)
  ---------------------------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------
  Molecular tests                                                                                                                                                                                                                                   
  Mismatch repair immunohistochemistry                                                           175                                           Expert opinion, Dr Tony Badrick, RCPAQAP (e‐mail)                                                    88--350[†](#jgh14154-note-0004){ref-type="fn"}
  *MLH1* methylation testing                                                                     314                                           Expert opinion, Dr Benhur Amanuel, PathWest Laboratory Medicine (e‐mail)                             157--628[†](#jgh14154-note-0004){ref-type="fn"}
  *BRAF* V600E testing                                                                           231                                           MBS Online[22](#jgh14154-bib-0022){ref-type="ref"}                                                   115--462[†](#jgh14154-note-0004){ref-type="fn"}
  Combined diagnostic genetic test MLH1, MSH2, and MSH6[‡](#jgh14154-note-0005){ref-type="fn"}   1400                                          Expert opinion, Dr Karen Carpenter, PathWest Diagnostic Genomics (e‐mail)                            700--2800[†](#jgh14154-note-0004){ref-type="fn"}
  Diagnostic genetic test PMS2[§](#jgh14154-note-0006){ref-type="fn"}                            1000                                          500--2000[†](#jgh14154-note-0004){ref-type="fn"}                                                     
  Genetic counseling[¶](#jgh14154-note-0007){ref-type="fn"}                                                                                                                                                                                         
  Initial session                                                                                267[††](#jgh14154-note-0008){ref-type="fn"}   Expert opinion, Anne Hawkins and Cassandra Nichols, Genetic Services of Western Australia (e‐mail)   92--455[‡‡](#jgh14154-note-0009){ref-type="fn"}
  LS diagnosis                                                                                   251[††](#jgh14154-note-0008){ref-type="fn"}   78--438[‡‡](#jgh14154-note-0009){ref-type="fn"}                                                      
  LS inconclusive                                                                                22[††](#jgh14154-note-0008){ref-type="fn"}    7--36[‡‡](#jgh14154-note-0009){ref-type="fn"}                                                        

All costs are presented in 2016 Australian dollars.

Extrapolated range based on 50% reduction and a twofold increase.

Based on Illumina TruSight Cancer MPS panel (San Diego, California, USA) and two MLPA kits (MRC‐Holland, Amsterdam, The Netherlands) for MLH1, MSH2, and MSH6.

Based on long‐range PCR followed by Sanger sequencing and MLPA for PMS2.

Costs for genetic counseling vary according to the complexity of the counseling provided. To calculate the cost of the genetic counseling, we first established a range of costs using the shortest and longest duration of genetic counseling and the least to most complex counseling scenarios. The average of these values was used in the analysis. Costs are divided into initial cost for genetic counseling, which includes planning and preparation for individual consultations, and follow‐up costs, which vary depending on the outcome of the genetic test.

Mean cost of providing each service.

Range based on minimum duration and complexity to maximum duration and complexity of counseling service.

LS, Lynch syndrome; MLPA, Multiple Ligation‐dependent Probe Amplification; MPS, Massive Parallel Sequencing; PCR, polymerase chain reaction; RCPAQAP, Royal College of Pathologists of Australasia Quality Assurance Program.

All costs are presented in 2016 Australian dollars, and as they are incurred in a single year, no discounting is required.

Outcomes {#jgh14154-sec-0012}
--------

For each screening pathway, our decision analysis model estimated the annual yield and costs of identifying LS in the four age‐restricted scenarios per 1000 CRC cases.

Sensitivity analyses {#jgh14154-sec-0013}
--------------------

To evaluate the robustness of our model outcomes, we conducted a number if univariate analyses. Firstly, we assessed the uncertainty of the diagnostic accuracy by calculating the 95% confidence intervals around the probability of being diagnosed with LS after demonstrating MMR deficiency using the Wilson confidence interval. This provided lower and upper confidence limits of yield and costs of LS screening in the CRC population.

Furthermore, as no cases of LS were diagnosed in CRC patients aged ≥ 70 years in our data set, we performed an analysis of the *MLH1*‐Pathway using age‐specific probabilities derived from Hampel *et al*.[30](#jgh14154-bib-0030){ref-type="ref"} to assess the impact of identifying LS cases in this age group. Unfortunately, similar data were not available from this research to assess the *BRAF*‐Pathway.

Finally, we reduced acceptance of genetic counseling to 92.5%[23](#jgh14154-bib-0023){ref-type="ref"} and varied the acceptance of germline testing to 81%[17](#jgh14154-bib-0017){ref-type="ref"} and 90%[23](#jgh14154-bib-0023){ref-type="ref"} to assess the impact of these variables on yield and costs of LS screening.

For all sensitivity analyses, we also explored the effect of varying costs parameters by assuming a 50% reduction and a twofold increase of all costs (Table [1](#jgh14154-tbl-0001){ref-type="table"} and tables in the [Supporting Information](#jgh14154-supitem-0001){ref-type="supplementary-material"}). This provided lower and upper bound cost estimates for each age cohort in the analyses.

Results {#jgh14154-sec-0014}
=======

*MLH1*‐Pathway {#jgh14154-sec-0015}
--------------

By restricting testing to CRC cases diagnosed \< 50 years, 76 (7.6%) of the 1000 CRC cases would be tested with IHC, leading to the identification of 5.2 LS cases. Total costs for this pathway were \$36 864 per 1000 CRC cases, equating to \$7041 per LS case diagnosed.

By expanding screening to include those aged between 50 and 59 years (screening \< 60), an extra 142 individuals (totaling 21.8% of total CRC patient population) would be tested with IHC to identify 1.5 additional LS cases (6.7 LS cases in total). This would cost an additional \$36 794 or \$25 177 per additional LS case diagnosed. Cost per case detected increased to \$10 999.

With further expansion to also screen CRC cases aged between 60 and 69 years (screening \< 70), an additional 255 individuals (totaling 47.3% of total CRC patient population) would be tested by IHC. This identified 1.6 additional LS cases (8.3 LS cases in total), annual program cost increased to \$138 663, and the cost per additional case detected was \$40 278. Cost per case detected increased to \$16 685.

Based on our data, universal screening would not identify any additional LS cases; however, annual program cost would increase by \$158 724 to \$297 387 per 1000 CRC cases. Cost per LS case detected increased to \$35 784.

*BRAF*‐Pathway {#jgh14154-sec-0016}
--------------

The *BRAF*‐Pathway identified the same number of LS cases as the *MLH1*‐Pathway at higher costs (Table [2](#jgh14154-tbl-0002){ref-type="table"}). For example, screening \< 50 identified 5.2 LS cases per 1000 CRC cases and cost \$36 462 for the *MLH1*‐Pathway and \$37 177 in the *BRAF*‐Pathway. Therefore, LS screening based on IHC followed by *BRAF* V600E is more expensive than the alternative, and the *BRAF*‐Pathway is subsequently dominated in terms of cost‐effectiveness.

###### 

Yield and costs for each pathway and age restricted scenario per 1000 individuals diagnosed with colorectal cancer

                    Number of CRC cases undergoing IHC testing[†](#jgh14154-note-0012){ref-type="fn"}, [§](#jgh14154-note-0014){ref-type="fn"}   Number of MMR‐deficient cases detected by IHC[‡](#jgh14154-note-0013){ref-type="fn"}, [§](#jgh14154-note-0014){ref-type="fn"}   Number of MMR‐deficient cases diagnosed as LS[§](#jgh14154-note-0014){ref-type="fn"}   *MLH1*‐Pathway        *BRAF*‐Pathway                                                                                                                      
  ----------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- --------------------- ---------------- --------- -------- -------- -------- -------- --------------------- --------- --------- -------- -------- -------- --------
  Screening \< 50   76                                                                                                                           10                                                                                                                              5.2                                                                                    36 864                17 726           72 441      7041     3386    13 837    7041   37 177                 17 869    73 042     7101     3413    13 952    7101
  Screening \< 60   218 (+ 142)                                                                                                                  19 (+ 9)                                                                                                                        6.7 (+ 1.5)                                                                            73 657 (+ 36 794)     35 823           145 482    10 999    5349    21 724   25 177  77 414 (+ 40 237)      37 613    152 834   11 560    5617    22 822   27 533
  Screening \< 70   473 (+ 255)                                                                                                                  41 (+ 22)                                                                                                                       8.3 (+ 1.6)                                                                            138 663 (+ 65 006)    67 893           274 703    16 685    8169    33 054   40 278  147 520 (+ 70 106)     72 110    292 032   17 751    8677    35 140   43 438
  Universal         1000 (+ 527)                                                                                                                 134 (+ 93)                                                                                                                      8.3 (+ 0)                                                                              297 387 (+ 158 724)   146 444          590 673    35 784   17 621   71 074    ---    349 674 (+ 202 154)    171 418   693 115   42 076   20 626   83 401    ---

All costs are presented in 2016 Australian dollars.

Number of cases undergoing IHC testing is determined by age at CRC diagnosis. Probability of meeting inclusion criteria in the age restricted scenarios is based on the age distribution of CRC incidence data from 2008 to 2012.[8](#jgh14154-bib-0008){ref-type="ref"}

Number of MMR cases detected is a subset of the number undergoing IHC testing

Figures in parentheses represent increase from previous screening scenario

CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair.

Sensitivity analyses {#jgh14154-sec-0017}
--------------------

When the probability of a diagnosis of LS was altered, our results changed significantly (Table [S1](#jgh14154-supitem-0001){ref-type="supplementary-material"}). Although overall costs remained similar to the original analysis, in the lower bound analysis, the number of LS cases diagnosed reduced to between 3.2 and 3.8, while the cost per LS case diagnosed increased ranged from \$11 521 to \$79 091. The reverse was true for the upper bound analysis where the number of LS cases diagnosed increased to between 7.0 and 23.7 and cost per case detected ranged from \$5350 to \$13 731. A similar pattern was seen when the age‐specific probabilities derived from Hampel *et al*.[23](#jgh14154-bib-0023){ref-type="ref"} were applied to the *MLH1*‐Pathway. Using these data, the number of LS cases diagnosed in each age restricted scenario was higher, and the cost per LS case diagnosed was lower. However, program costs remained similar to our original analysis ([Table S2](#jgh14154-supitem-0001){ref-type="supplementary-material"}).

Lowering adherence to genetic counseling and germline testing reduced diagnostic yield by up to 25%. This resulted in a slight reduction in total costs (5--15% for *MLH1*‐Pathway and 7--15% for *BRAF*‐Pathway), while the cost per LS case detected increased (8--24% for *MLH1*‐Pathway and 8--21% for *BRAF*‐Pathway) ([Table S3](#jgh14154-supitem-0001){ref-type="supplementary-material"}). Similar results were found when both costs and acceptance of genetic counseling and germline testing were altered.

Changes to the cost parameters affected the costs proportionally (Table [2](#jgh14154-tbl-0002){ref-type="table"} and tables in the [Supporting Information](#jgh14154-supitem-0001){ref-type="supplementary-material"}).

Discussion {#jgh14154-sec-0018}
==========

We developed a decision analysis model and used empirical data[18](#jgh14154-bib-0018){ref-type="ref"} to determine the cost and yield of screening for LS per 1000 CRC cases. Based on our results, screening for LS using the *MLH1*‐Pathway is more cost‐effective than the *BRAF*‐Pathway. Limiting screening to CRC cases aged under 50 years in the *MLH1*‐Pathway would identify 5.2 LS cases per 1000 CRC cases for the overall lowest cost, with a cost per LS case detected of \$7041. Expanding this pathway to also screen individuals aged 50--59 years (screening \< 60) increased diagnostic yield by 28% (1.5 cases). This was associated with a doubling of program costs, an increase in cost per LS case detected (to \$10 999) and an incremental cost of \$25 177 to detect one additional case. Screening \< 70 further increased diagnostic yield of screening with program costs increasing by 88%. Cost per case detected in this scenario increased to \$16 685, equating to an incremental cost per additional case detected of \$40 278. Universal screening more than doubled program costs compared with screening \< 70 for no additional yield; however, this was because no LS cases were identified in this age group in our dataset. Cost per LS case detected increased to \$35 784. The *BRAF*‐Pathway identified the same number of LS cases; however, costs were higher for all age‐at‐diagnosis thresholds.

There remains ongoing discussion about the optimal age to stop screening for LS in the CRC‐affected population,[4](#jgh14154-bib-0004){ref-type="ref"}, [21](#jgh14154-bib-0021){ref-type="ref"} and our model, like others,[24](#jgh14154-bib-0024){ref-type="ref"}, [25](#jgh14154-bib-0025){ref-type="ref"}, [26](#jgh14154-bib-0026){ref-type="ref"}, [27](#jgh14154-bib-0027){ref-type="ref"} demonstrates that applying age restrictions to screening criteria results in fewer LS cases being identified. This impacts patient care and has downstream effects for at‐risk relatives who would not be identified, thereby diminishing the opportunity to commence interventions to reduce mortality and morbidity in this cohort. However, concerns have been raised about the feasibility of expanded screening for LS, particularly in relation to the associated costs.[24](#jgh14154-bib-0024){ref-type="ref"} While individuals with LS are at higher risk of LS‐related cancers compared with the general population, the likelihood of developing such a cancer diminishes with age.[14](#jgh14154-bib-0014){ref-type="ref"} This suggests that, while expanding screening to include older individuals will identify more cases, the increased detection will likely come at the expense of efficiency. In our model, the proportion of CRC cases who demonstrate MMR protein loss by IHC and are subsequently found to be LS positive was highest in the screening \< 50 scenario (52% for both pathways). This congruency reduced in the expanded alternatives (ranging from 0% to 16%), demonstrating that although screening older individuals may detect additional LS cases, it does so by conducting disproportionately greater numbers of tests which results in higher program costs. This increase in overall cost could be considerable, with our model demonstrating that universal screening cost was more than twice as much as screening \< 70 with no additional benefit in LS carrier detection.

Based on our results, there is added benefit in ensuring CRC cases \< 70 years are screened and although this requires an increase in total program cost, such an expansion could be considered a reasonable trade‐off between costs and yield.[25](#jgh14154-bib-0025){ref-type="ref"}, [27](#jgh14154-bib-0027){ref-type="ref"} While our model suggests there is no additional benefit of universal screening compared with screening \< 70, this is due to the lack of LS cases identified in this age cohort in our study population. As other investigations have confirmed the existence of CRC‐affected LS mutation carriers in this age group,[19](#jgh14154-bib-0019){ref-type="ref"}, [28](#jgh14154-bib-0028){ref-type="ref"} we conducted a sensitivity analysis where we assessed the impact of adjusting the proportion of individuals who were MMR deficient but were not confirmed with LS (Table [S1](#jgh14154-supitem-0001){ref-type="supplementary-material"}). In the case of universal screening, increasing this proportion of individuals diagnosed with LS dramatically reduced the cost per LS case diagnosed (to between \$14 000 and \$15 000) and the cost per additional LS diagnosis (approximately \$25 000). In a second analysis, we applied the age‐specific probabilities of a US study evaluating the *MLH1*‐Pathway.[30](#jgh14154-bib-0030){ref-type="ref"} Using these probabilities, we found similar overall program costs for universal screening with a cost per additional LS case detected of approximately \$50 000 ([Table S2](#jgh14154-supitem-0001){ref-type="supplementary-material"}). These results indicate that while there is potential benefit in screening CRC cases ≥ 70 years in terms of yield, cost‐effectiveness of such an expansion will be significantly impacted by the proportion of LS cases in this age cohort. Further studies with larger samples are needed to enable more precise estimates.

Although screening for LS has shown to be cost‐effective, consensus of the optimal strategy is yet to be achieved. To our knowledge, few studies have presented results based on age‐restricted inclusion criteria for the two pathways we investigated. One analysis investigating the *BRAF*‐Pathway to screen for LS found it was cost‐effective to screen for LS in those aged \< 70 years.[27](#jgh14154-bib-0027){ref-type="ref"} A second study found using MSI, in conjunction with IHC, to be cost‐effective across different age restrictions.[25](#jgh14154-bib-0025){ref-type="ref"} However, when we investigated MSI in our preliminary analyses, we found its inclusion was more costly than the alternative strategies for all age cohorts with limited benefit (results not shown). Analyses of universal screening using the *MLH1*‐Pathway have indicated that while this strategy is cost‐effective, it was not as cost‐effective as possible alternatives, with one study determining it was more cost‐effective to include both *MLH1* methylation and *BRAF* V600E testing after IHC,[29](#jgh14154-bib-0029){ref-type="ref"} and the other finding cost‐effectiveness improved when CRC cases were first triaged with the revised Bethesda guidelines.[30](#jgh14154-bib-0030){ref-type="ref"} We have previously noted that implementation of clinical guidelines in routine practice is poor,[4](#jgh14154-bib-0004){ref-type="ref"}, [16](#jgh14154-bib-0016){ref-type="ref"}, [17](#jgh14154-bib-0017){ref-type="ref"} this would likely impact the effectiveness of this strategy, leading to missed opportunities to diagnose LS and reduced cost‐effectiveness. While universal screening using *BRAF*‐Pathway has also been shown to be cost‐effective,[26](#jgh14154-bib-0026){ref-type="ref"}, [27](#jgh14154-bib-0027){ref-type="ref"}, [29](#jgh14154-bib-0029){ref-type="ref"}, [31](#jgh14154-bib-0031){ref-type="ref"} two studies indicated that this strategy was not as effective as alternative strategies that included predictive modeling as a first step[26](#jgh14154-bib-0026){ref-type="ref"} and the inclusion of both *BRAF* V600E and *MLH1* methylation testing.[29](#jgh14154-bib-0029){ref-type="ref"} When we assessed the *BRAF*‐Pathway, we found it to be as effective but more expensive than the *MLH1*‐Pathway at all age thresholds. This was due to the increased number of individuals undergoing germline testing in the *BRAF*‐Pathway as *BRAF* V600E only achieves \~75% efficiency as a surrogate marker for *MLH1*‐methylated sporadic CRC showing loss of MLH1/PMS2.[18](#jgh14154-bib-0018){ref-type="ref"} Only one other study has made a direct comparison between the two pathways we investigated, and although the authors determined that the *BRAF*‐Pathway was more cost‐effective than the *MLH1*‐Pathway, the differences were small.[29](#jgh14154-bib-0029){ref-type="ref"}

Benefits of an LS screening program are dependent on ensuring all eligible CRC cases are screened and that those detected with MMR‐deficiency receive genetic counseling and germline testing. In our analysis, we assumed all eligible cases would undergo appropriate testing; however, we recognize that this may not occur in practice,[17](#jgh14154-bib-0017){ref-type="ref"}, [32](#jgh14154-bib-0032){ref-type="ref"} as individuals may not wish to participate in genetic testing because of, among other things, possible negative psychological impacts (such as anxiety and depression) and concerns over personal information.[33](#jgh14154-bib-0033){ref-type="ref"} Reducing the proportion of MMR‐deficient individuals who agree to genetic counseling and subsequently agree to germline testing decreases yield and total cost in all scenarios, while increasing cost per additional LS case detected. Importantly, such reductions lead to more undiagnosed cases of LS and missed opportunities to identify and monitor at‐risk relatives. The greatest benefits of LS screening will only be achieved if screening is appropriately implemented and eligible cases have appropriate and informed access to genetic counseling and germline testing.

An important strength of this study is that the model parameters are derived from two large population‐based studies for LS testing and our results align with previous estimates of LS in the CRC population.[19](#jgh14154-bib-0019){ref-type="ref"}, [34](#jgh14154-bib-0034){ref-type="ref"} However, despite this, three limitations are of note. Firstly, this analysis only examined testing incident CRC cases with IHC. However, while we acknowledge that MSI testing, either with or without IHC, is an alternative pathway for triaging CRC cases,[16](#jgh14154-bib-0016){ref-type="ref"}, [23](#jgh14154-bib-0023){ref-type="ref"} our preliminary analyses indicated that this pathway was substantially more expensive, and therefore, we excluded it from further investigations.

Secondly, this analysis only considers costs to identify LS in CRC cases and does not take into account the subsequent costs and cost savings of cascade screening and surveillance of at‐risk relatives. While predictive genetic testing of at‐risk relatives has been shown to be cost saving in Australia,[35](#jgh14154-bib-0036){ref-type="ref"} there is currently no research into the cost‐effectiveness of surveillance in LS carriers. Research with similar cost per LS case detected to ours, which also assessed costs and benefits of surveillance in this group found screening for LS in those aged \< 50 gained 43.6 life year (\$7938/LYG).[25](#jgh14154-bib-0025){ref-type="ref"} When screening was expanded to include those aged 51--60 years, a further 118 life years were gained (\$6380 per additional LYG). An additional 44.3 life years were gained when those aged 61--70 years were screened (\$10 648 per additional LYG). This suggests that with our cost per case detected, cascade screening and surveillance of at‐risk individuals will be cost‐effective at a willingness‐to‐pay threshold of \$50 000. As much of the benefit in identifying LS relates to gains in life expectancy in this group,[36](#jgh14154-bib-0037){ref-type="ref"} future research should incorporate analyses of these implications and costs.

Finally, data around the costs of laboratory testing for LS have been difficult to obtain, and our costs may not necessarily reflect the range of costs throughout Australia. To account for this, we conducted sensitivity analyses to provide the lower and upper cost estimates.

Conclusions {#jgh14154-sec-0019}
===========

Based on our analysis, *MLH1* methylation testing as a follow‐up for CRCs showing loss of MLH1 protein expression is more cost‐effective than *BRAF* V600E somatic mutation testing in identifying LS cases. An expanded screening program that includes screening CRC cases diagnosed \<70 years will identify more LS cases at a reasonable cost. Future research into the yield of LS screening in CRC patients ≥ 70 years and the potential to offset additional costs by identifying at‐risk relatives is needed to determine if universal screening is justified.

Supporting information
======================

###### 

**Table S1.** Yield and costs for each pathway and age restricted scenario per 1,000 individuals diagnosed with colorectal cancer for the sensitivity analyses with a) the lower bound confidence boundary and b) upper bound confidence boundary.

**Table S2.** Yield and costs for each pathway and age restricted scenario per 1,000 individuals diagnosed with colorectal cancer for the sensitivity analyses using data from Hampel and colleagues.

**Table S3.** Yield and costs for each pathway and age restricted scenario per 1,000 individuals diagnosed with colorectal cancer for the sensitivity analyses a) when attendance at genetic counselling reduced to 92.5% and acceptance of genetic testing reduced to 81% and b) when attendance at genetic counselling reduced to 92.5% and acceptance of genetic testing reduced to 90%.

###### 

Click here for additional data file.
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